Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults

Josep Font, Ricard Cervera, Gerard Espinosa, Lucio Pallarés, Manel Ramos-Casals, Sonia Jiménez, Mario García-Carrasco, Luis Seisdedos, Miguel Ingelmo

Abstract

Objective—To define the pattern of disease expression in patients with childhood onset systemic lupus erythematosus (SLE).

Methods—Prospective analysis of clinical manifestations and immunological features of 34 patients in whom the first manifestations appeared in childhood from a series of 430 unselected patients with SLE.

Results—Thirty one (91%) patients from the childhood onset group were female and three male (9%) (ratio female/male, 10/1, with no difference compared with the adult onset group). Mean age of this group at disease onset was 11 years (range 5–14) compared with 32 years (15–48) for the adult onset group. Mean age of this group at disease onset was 11 years (range 5–14) compared with 32 years (15–48) for the remaining patients. The childhood onset patients more often had nephropathy (20% v 9% in adult onset SLE, p=0.04; OR:2.7; 95% CI:1.1, 7), fever (41% v 21%, p=0.006; OR:2.6, 95% CI:1.2, 5.7), and lymphadenopathy (6% v 0.5%, p=0.03, OR:12.3, 95% CI:1.2, 127.6), as presenting clinical manifestations. During the evolution of the disease, the childhood onset patients had an increased prevalence of malar rash (79% v 51%, p=0.002; OR:3.7; 95% CI:1.5, 9.5) and chorea (9% v 0%, p<0.0001). This group exhibited a higher prevalence of anticardiolipin antibodies (aCL) of the IgG isotype when compared with the remaining patients (29% v 13%, p=0.017; OR:2.9, 95% CI:1.2, 6.8). No significant differences were found among the other antibodies between the two groups.

Childhood onset patients more often received azathioprine (15% v 6%, p=0.00004; OR:11.2; 95% CI:2.8, 44.9) but no differences were detected between the groups concerning side effects or drug toxicity.

Conclusions—The presentation and the clinical course of SLE varied in this series of 430 patients depending on their age at disease onset. Nephropathy, fever, and lymphadenopathy were more common in childhood onset patients as presenting clinical manifestations, while malar rash, chorea, and detection of IgG aCL were more common during the evolution of the disease.

Table 1 Clinical manifestations at the onset of SLE in the childhood onset patients compared with the adult onset patients

<table>
<thead>
<tr>
<th>Manifestations</th>
<th>Childhood onset (n=34)</th>
<th>Adult onset (n=396)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malar rash</td>
<td>15 (44)</td>
<td>139 (35)</td>
<td>NS</td>
</tr>
<tr>
<td>Discoid lesions</td>
<td>0 (0)</td>
<td>13 (3)</td>
<td>NS</td>
</tr>
<tr>
<td>Subacute cutaneous lesions</td>
<td>0 (0)</td>
<td>14 (3)</td>
<td>NS</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>8 (23)</td>
<td>80 (20)</td>
<td>NS</td>
</tr>
<tr>
<td>Oral ulcers</td>
<td>3 (9)</td>
<td>51 (13)</td>
<td>NS</td>
</tr>
<tr>
<td>Arthritis</td>
<td>22 (65)</td>
<td>247 (62)</td>
<td>NS</td>
</tr>
<tr>
<td>Steroid</td>
<td>4 (12)</td>
<td>51 (13)</td>
<td>NS</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>7 (20)</td>
<td>35 (9)</td>
<td>0.04</td>
</tr>
<tr>
<td>Neurological involvement</td>
<td>0 (0)</td>
<td>26 (6)</td>
<td>NS</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>4 (12)</td>
<td>35 (9)</td>
<td>NS</td>
</tr>
<tr>
<td>Haemolytic anaemia</td>
<td>3 (9)</td>
<td>11 (3)</td>
<td>NS</td>
</tr>
<tr>
<td>Fever</td>
<td>14 (41)</td>
<td>83 (21)</td>
<td>0.006</td>
</tr>
<tr>
<td>Raynaud’s phenomenon</td>
<td>4 (12)</td>
<td>62 (16)</td>
<td>NS</td>
</tr>
<tr>
<td>Livedo reticularis</td>
<td>1 (3)</td>
<td>2 (0.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>0 (0)</td>
<td>3 (1)</td>
<td>NS</td>
</tr>
<tr>
<td>Myositis</td>
<td>1 (3)</td>
<td>15 (4)</td>
<td>NS</td>
</tr>
<tr>
<td>Lung involvement</td>
<td>0 (0)</td>
<td>5 (1)</td>
<td>NS</td>
</tr>
<tr>
<td>Chorea</td>
<td>1 (3)</td>
<td>0 (0)</td>
<td>NS</td>
</tr>
<tr>
<td>Sicca syndrome</td>
<td>0 (0)</td>
<td>2 (0.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>2 (6)</td>
<td>2 (0.5)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

form. Salient features included in this protocol were: (1) age at onset of the disease, (2) age at diagnosis, defined as the age when the patient fulfilled four or more of the 1982 revised ARA criteria for the classification of SLE, (3) time of evolution of the disease, defined as the time from the onset until the present study, (4) clinical manifestations at the onset, (5) cumulative clinical manifestations during the evolution of the disease, and (6) laboratory features at diagnosis. Information collected into the protocol forms was transferred to a computerised database program (DBASE IV).

DEFINITION OF CLINICAL FEATURES

To minimise possible inter-observer bias, the variables of this protocol were carefully discussed by all the participating physicians on several occasions. The clinical manifestations evaluated in this protocol were defined according to the ARA glossary committee. 3

LABORATORY STUDIES

Antinuclear antibodies (ANA) were determined by indirect immunofluorescence using mouse liver as substrate and regarded as positive if higher than 1:100. Anti-dsDNA antibodies were determined with Farr’s ammonium sulphate precipitation technique and considered as positive if higher than 7 U/ml. Precipitating antibodies to extractable nuclear antigens (ENA), including Ro(SSA), La(SSB), U1-snRNP and Sm were detected by counter-immunoelectrophoresis using calf and rabbit thymus and human spleen extracts. Rheumatoid factor (RF) was detected by latex test and regarded as positive if higher than 25 UI/ml. Anticardiolipin antibodies (aCL) of the IgG and IgM isotypes were measured by an ELISA method as described by Gharavi et al 10 with minor modifications of our own. 9 The results were expressed as negative or low, moderate, or high positive, according to the recommendations of the 1986 workshop on standardisation of the aCL test. 11 The lupus anticoagulant (LA) activity was detected by coagulation assays in platelet free plasma obtained by double centrifugation following the recommendations of the Subcommittee on LA of the Scientific and Standardisation Committee of the International Society of Thrombosis and Hemostasis. 12

STATISTICAL ANALYSIS

Conventional χ² and Fisher’s exact tests were used for analysing qualitative differences, and Student’s t test for comparison of means in large independent samples of similar variance. A p<0.05 value was taken to indicate statistical significance. When several independent variables appeared to have statistical significance in the univariate analysis, a logistic regression test was performed for multivariate analysis to rule out possible confounding variables. In this case, only those variables showing statistical significance in the multivariate analysis were considered as significant in the results of the study. The odds ratio (OR) was calculated for assessing the risk of appearance of each variable. A lower limit of the 95% confidence intervals (CI) that exceeded 1.0 was taken to indicate statistical significance in the case of positive association and upper limit lower than 1.0 in the case of negative association. Results of the analysis of continuous variables are indicated as mean (SD). This statistical analysis was performed by means of the SPSS/PC 4.0 and EPISTAT programs using the information stored in the database program.

Results

PATIENTS

Thirty one (91%) patients from the childhood onset group were female and three male (9%) (ratio female/male, 10:1, with no difference compared with the adult onset group). Mean age of this group at disease onset was 11 years (range 5–14) compared with 32 years (15–48) for the remaining patients. Mean age at diagnosis of SLE of childhood onset patients was 14 years (range 6–28) compared with 34 years (15–85) for the adult onset patients. The interval between the time of onset and diagnosis was three years in the childhood onset group.
compared with two years in the adult onset group (difference not significant). Mean time of evolution of the disease in the childhood onset group was 85 months (range 1–264) and in the adult onset group was 73 months (1–528) (difference not significant).

**CLINICAL MANIFESTATIONS**

Table 1 shows the presenting clinical manifestations for patients with disease onset before or after age 14. The childhood onset patients more often experienced nephropathy (20% vs 9% in adult onset SLE; p=0.04; OR:2.7; 95%CI:1.1, 7), fever (41% vs 21%; p=0.006; OR:2.6, 95%CI:1.2, 5.7), and lymphadenopathy (6% vs 0.5%; p=0.03; OR: 12.3, 95%CI: 1.2, 127.6). During the evolution of the disease (table 2), the childhood onset patients more often presented malar rash (79% vs 51%; p=0.002; OR:3.7; 95%CI:1.5, 9.5) and chorea (9% vs 0%; p<0.001). The frequency of other clinical features, including serositis, central nervous system manifestations and pulmonary disease, did not differ significantly between the groups.

**IMMUNOLOGICAL FEATURES**

Table 3 gives the main immunological findings of childhood onset patients. This group more frequently exhibited a positive level of antiphospholipid antibodies (aCL) of the IgG isotype when compared with the remaining patients (29% vs 13%, p=0.017; OR:2.9, 95%CI:1.2, 6.8). No significant differences were found among the other antibodies between the two groups.

**TREATMENT AND SIDE EFFECTS**

Table 4 summarises the main SLE treatments prescribed during the study period. Childhood onset patients more often received azathioprine when compared with the remaining patients (15% vs 6%; p=0.00004; OR:11.2; 95%CI:2.8, 44.9). No differences were detected between the groups concerning side effects or drug toxicity (table 5).

**Discussion**

There have been several studies dealing with childhood onset SLE and their results suggested that age at onset modifies the expression of the disease in terms of clinical presentation, pattern of organ involvement, and serological findings. However, the true prevalence of childhood onset SLE among the SLE population is unknown. One of the reasons is that there is not strict definition of childhood onset SLE. The most often used cut off ages are 14 or 16 years at onset of disease or at diagnosis. However several studies use a higher or lower cut off age. In our series, of 430 patients with SLE developed the initial manifestations clearly attributable to the disease before the age of 14. In other series, the prevalence of childhood SLE in children younger than 16 is nearly 15%.

The onset of SLE is rare before the age of 5 years. In our series, one patient presented clinical manifestations of SLE at the age of 5 years but none of our patients presented these manifestations before this age.

The female to male ratio in adult onset SLE is generally found to be slightly more than 10:1. A higher proportion of men is often reported in childhood onset SLE in some series, but not in others. In our series, men represented 9% of the cases of childhood onset SLE with a female to male ratio similar to that in the adult onset SLE.

Although there are many previous publications of paediatric SLE, the strength of this study is that, unlike many others, it compares children and adults from the same clinical population. Comparison of the clinical features at onset between childhood onset and adult onset patients reveals both similarities and important differences. The frequency of skin, joint, serositis, and haematological disease was similar in both groups and correlates with previous reports. However, childhood onset SLE patients had more frequently renal involvement, fever, and lymphadenopathy, as has also been reported by other authors.

Nephropathy is often described in childhood onset SLE, although this manifestation has been more frequently described in North American series—especially in children with a Central and South American Hispanic background—than in European patients. In our cohort, which includes all the patients diagnosed as having SLE in our areas, 20% of childhood onset SLE patients presented...
nephropathy as initial clinical manifestation. Severity in this disease is closely related to renal involvement. Thus, SLE pattern is generally more severe in children than in adults. This inverse correlation between the severity of the disease and the age of diagnosis has been noted since the earlier series. However, a striking finding is the additional organ system involvement over the course of follow up in both adults and children. As time goes on, prevalence of renal involvement is similar in both groups of age. The main significant differences during the evolution of the disease are the more common prevalence of malar rash and chorea in the childhood onset group, correlating with previous reports. It is of note that the treatment given to children was similar to that given to adults, except for a more common use of azathioprine in childhood onset patients. No differences were detected between the groups concerning side effects or drug toxicity.

Comparison of the autoantibody profiles of adults and childhood cases shows a similar frequency of increased anti-dsDNA and positive ANA in both groups. These data are in contrast with previous reports in which the frequency of these antibodies is higher in childhood than adult cases. The only significant difference between the two groups is the higher presence of IgG aCL in children than in adult patients. However, there was not any case of thrombosis in childhood onset during the follow up period.

We conclude that the presentation and the clinical course of SLE varied in our series of 430 patients depending on their age at disease onset. Nephropathy, fever, and lymphadenopathy were more common in childhood onset patients as presenting clinical manifestations, while malar rash, chorea, and detection of IgG aCL were more common during the evolution of the disease.

Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults

Josep Font, Ricard Cervera, Gerard Espinosa, et al.

doi: 10.1136/ard.57.8.456